Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia-Reference-Cited by-同舟云学术

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia

Published:2014-10-28 Issue:23 Volume:5 Page:12371-12382
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Alachkar Houda¹,Mutonga Martin B.G.¹,Metzeler Klaus H.²³,Fulton Noreen¹,Malnassy Gregory¹,Herold Tobias²³,Spiekermann Karsten²³,Bohlander Stefan K.⁴,Hiddemann Wolfgang²³,Matsuo Yo⁵,Stock Wendy¹,Nakamura Yusuke¹

Affiliation:

1. Department of Medicine, University of Chicago, Chicago, IL

2. Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany

3. Clinical Cooperative Group Leukemia, Helmholtz Center Munich for Environmental Health, München, Germany

4. Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand

5. OncoTherapy Science, Inc., Kanagawa, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application;Clinical and Translational Oncology;2024-08-26

2. Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity;Cancer Letters;2023-04

3. Structural classification of MELK inhibitors and prospects for the treatment of tumor resistance: A review;Biomedicine & Pharmacotherapy;2022-12

4. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer;PLOS ONE;2022-06-24

5. Pyrazolopyridine: An efficient pharmacophore in recent drug design and development;Chemical Biology & Drug Design;2022-06-16